From Inflection To Insight: Vertex And Merck’s Dueling HCV Drugs

Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.

The Ongoing 'From Inflection To Insight' Series Will Reveal Lessons From Past Chapters In Biopharma • Source: Shutterstock

Key Takeaways:

  • Vertex’s Incivek was the fastest drug from launch to $1bn, while Merck’s competing Victrelis generated a fraction of the revenue

The pharmaceutical industry is no stranger to fierce competition, but the battle between Vertex Pharmaceuticals Incorporated’s Incivek (telaprevir) and Merck & Co., Inc.’s Victrelis (boceprevir) stands out as a particularly captivating David versus Goliath story. Incivek was Vertex’s first drug to market and has gone down in the annals of history as the fastest to reach $1bn, doing so in less than a year of launching. Meanwhile, Victrelis was marketed by one of the most established big pharma companies but brought in a tenth of that amount during the same time.

Victrelis was launched 13 May 2011 and Incivek was green-lighted 10 days later. Both drugs were indicated for hepatitis C...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By 

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

More from In Vivo

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.